Patient characteristics based on the presence or absence of plasmacytomas
| . | No plasmacytomas (n = 30) . | Plasmacytomas (n = 33) . | P value . |
|---|---|---|---|
| Age (y) at inclusion (median, range) | 59 (53-65) | 59 (50-67) | .875 |
| Sex (female, %) | 16 (53.33) | 13 (39.40) | .268 |
| Heavy chain type (n, %) | .827 | ||
| IgG | 14 (46.7) | 17 (54.8) | |
| IgA | 10 (33.3) | 7 (22.6) | |
| IgD | 1 (3.3) | 1 (3.2) | |
| Bence Jones | 5 (16.7) | 6 (19.4) | |
| κ light chain type (n, %) | 18 (60.0) | 18 (54.6) | .662 |
| High-risk cytogenetics∗ (n, %) | 9 (31.0) | 5 (16.7) | .195 |
| PC BM % (median, range) | 20 (13-37) | 2 (1-11) | .093 |
| MC g/L (median, range) | 10.7 (1.2-20.6) | 10.3 (0-19.4) | .465 |
| Triple refractoriness† (n, %) | 23 (76.7) | 21 (63.6) | .260 |
| Penta refractoriness‡ (n, %) | 6 (20.0) | 12 (36.4) | .151 |
| Prior HCT (n, %) | |||
| Autologous | 27 (100) | 27 (93.1) | .165 |
| Allogeneic | 2 (7.4) | 4 (13.8) | .440 |
| . | No plasmacytomas (n = 30) . | Plasmacytomas (n = 33) . | P value . |
|---|---|---|---|
| Age (y) at inclusion (median, range) | 59 (53-65) | 59 (50-67) | .875 |
| Sex (female, %) | 16 (53.33) | 13 (39.40) | .268 |
| Heavy chain type (n, %) | .827 | ||
| IgG | 14 (46.7) | 17 (54.8) | |
| IgA | 10 (33.3) | 7 (22.6) | |
| IgD | 1 (3.3) | 1 (3.2) | |
| Bence Jones | 5 (16.7) | 6 (19.4) | |
| κ light chain type (n, %) | 18 (60.0) | 18 (54.6) | .662 |
| High-risk cytogenetics∗ (n, %) | 9 (31.0) | 5 (16.7) | .195 |
| PC BM % (median, range) | 20 (13-37) | 2 (1-11) | .093 |
| MC g/L (median, range) | 10.7 (1.2-20.6) | 10.3 (0-19.4) | .465 |
| Triple refractoriness† (n, %) | 23 (76.7) | 21 (63.6) | .260 |
| Penta refractoriness‡ (n, %) | 6 (20.0) | 12 (36.4) | .151 |
| Prior HCT (n, %) | |||
| Autologous | 27 (100) | 27 (93.1) | .165 |
| Allogeneic | 2 (7.4) | 4 (13.8) | .440 |
BM, bone marrow; HCT, hematopoietic stem cell transplant; IgH, immunoglobulin heavy chain; MC, monoclonal component; PC, plasma cells.
High-risk cytogenetics were considered for alterations in TP53, t(4,14) and/or t(14,16).
Refractoriness to a proteasome inhibitor, an immunomodulator, and an anti-CD38 drug.
Refractoriness to bortezomib, carfilzomib, lenalidomide, pomalidomide, and an anti-CD38 drug.